Abstracts

N-ACETYLCYSTEINE FOR ANTI-TB DRUG-INDUCED LIVER INJURY: A RANDOMISED CONTROLLED TRIAL

First-line anti-tuberculosis (TB) therapy can cause liver injury. N-Acetylcysteine (NAC) is widely used in patients with paracetamol toxicity and there is limited evidence of benefit in liver injury due to other causes. We conducted a randomised, double-blind, placebo-controlled trial to assess whether intravenous NAC improves liver recovery in adult patients admitted to hospital with first-line…

HIV, TUBERCULOSIS, AND CHRONIC LUNG DISEASE AMONG KENYAN ADULTS

People living with HIV (PLWH) are at increased risk for non-communicable diseases such as chronic lung disease (CLD) and also remain at risk for pulmonary opportunistic infections including tuberculosis (TB) that may contribute to the development of CLD. We hypothesized that prior active TB would independently increase the risk for CLD and sought to determine…

HIV VIROLOGICAL OUTCOMES DURING TENOFOVIR ALAFENAMIDE AND RIFABUTIN COADMINISTRATION

Tenofovir alafenamide (TAF) absorption may be decreased during rifabutin (RFB) therapy due to induction of P-glycoprotein.  Current USA HIV guidelines therefore recommend against coadministration of TAF and RFB. Based on expert opinion, some centres have administered TAF containing HIV regimens with RFB; however, clinical outcomes have not been assessed. Retrospective observational study of all individuals…

EARLY BACTERICIDAL ACTIVITY OF MEROPENEM (+ AMOX/CLAV) WITH & WITHOUT RIFAMPIN FOR TB

A dose finding study was conducted to measure the early bactericidal activity (EBA) of meropenem and amoxicillin/clavulanate, with or without rifampicin, in patients with pulmonary tuberculosis. In this Phase 2A RCT, patients with sputum smear-positive pulmonary TB were randomized to receive 14 days of:  Meropenem 2g TID plus Rifampicin 20 mg/kg (Arm C); Meropenem 2g TID (Arm D); Meropenem 1g…